Latest news with #AnthemBiosciencesLtd
India Today
14 hours ago
- Business
- India Today
Anthem Biosciences IPO fully booked: Should you subscribe? Check listing gains
The initial public offering (IPO) of Anthem Biosciences Ltd is getting strong attention from investors as bidding enters its final offer, which opened for subscription on July 14, aims to raise Rs 3,395 crore through a complete offer for sale (OFS) of 5.96 crore equity of July 15 (1:54 PM), the IPO was subscribed 2.40 times overall. The retail category was booked 1.66 times, while non-institutional investors (NII) showed strong interest with 6.71 times subscription. However, qualified institutional buyers (QIBs) had only subscribed 0.48 times by that price band is fixed at Rs 570 per share. The offer is entirely an OFS, which means that the company will not receive any funds from the issue. Instead, existing shareholders are selling their MARKET PREMIUM (GMP)The grey market premium (GMP) for Anthem Biosciences IPO has increased steadily. On July 15, the GMP stood at Rs 124, which suggests an estimated listing price of Rs 694 per share. This means the IPO could offer a potential gain of 21.75% over the upper price Biosciences is a contract research, development, and manufacturing organisation (CRDMO) operating in both small and large molecule spaces. It has handled over 8,000 projects and has more than 675 clients. The company currently has 242 active projects and has adopted technologies like ADC, RNAi, flow chemistry and green chemistry early on, making it a niche player in the pharmaceutical and biotech company is known for its integrated services across drug discovery, development, and manufacturing, giving it an edge in a competitive industry. It has a strong R&D focus and globally compliant infrastructure, with more than 100 successful audits over the past three BROKERAGES SAYAccording to SBI Securities, Anthem Biosciences is well placed to benefit from the fast-growing CRDMO industry. They pointed to its planned capacity expansion, strong pipeline, and history of profitable growth. SBI noted that the IPO is fairly priced when compared to its peers and recommended investors to subscribe at the cut-off price for long-term Rathi also gave a 'SUBSCRIBE' rating. It highlighted the company's strong client relationships, innovative focus on specialty ingredients and peptides, and a differentiated fee-for-service model. The report mentioned the company's profitability and growth outlook, even though the asking price implies a price-to-earnings (PE) ratio of 70.6 times based on annualised FY25 Equities' research analyst Rajan Shinde said that the IPO gives investors a chance to invest in the high-growth CRDMO segment. He added that Anthem's integrated capabilities across molecules, early adoption of advanced technologies, and strong project pipeline make it a standout in the also pointed out that although the asking valuation of 70x seems high at first, it is still below the average industry range of 80x to 90x. This gives investors a fair entry point, especially considering the company's consistent revenue growth and profit revenue rose by 34.3% in FY24 and by 30% in FY25. Net profit also recovered, jumping 22.9% in FY25 after falling 4.6% the year for the IPO will close on July 16. The allotment is expected on July 17, and the listing is likely to happen on July 21 on both the NSE and The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)- Ends
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Anthem Biosciences IPO subscribed 73 pc on Day 1 of offer
The initial share sale received bids for 3,21,13,406 shares against 4,40,70,682 shares on offer, according to NSE data Press Trust of India New Delhi The initial public offer of Anthem Biosciences Ltd got subscribed 73 per cent on the first day of share sale on Monday. The initial share sale received bids for 3,21,13,406 shares against 4,40,70,682 shares on offer, according to NSE data. Non-institutional Investors category garnered 1.55 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 58 per cent. The portion for Qualified Institutional Buyers (QIBs) received 37 per cent subscription. Anthem Biosciences has raised Rs 1,016 crore from anchor investors. The Rs 3,395-crore IPO of the Bengaluru-based firm will close on July 16. The price band has been fixed at Rs 540-570 per share. Since the IPO is entirely an offer-for-sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. JM Financial, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
